Khan, Caribou Biosciences CBO, sells $13598 in stock
#Caribou Biosciences #Insider Trading #CRBU stock #CAR-T cell therapies #Ruhi Ahmad Khan #Clear Street #Biotechnology investments #Restricted stock units
📌 Key Takeaways
- Ruhi Ahmad Khan sold 6,938 shares of Caribou Biosciences stock worth $13,598 to cover tax obligations
- Khan simultaneously acquired additional shares and options, maintaining a significant ownership stake of 104,998 shares
- CRBU stock has surged 32% in the past week and 73% over the past year, currently trading below its Fair Value
- Clear Street initiated coverage with a Buy rating and $13 price target, citing optimism about CAR-T cell therapies
📖 Full Retelling
Ruhi Ahmad Khan, Chief Business Officer of Caribou Biosciences (NASDAQ:CRBU), sold 6,938 shares of common stock on February 24, 2026, at $1.96 per share, totaling $13,598, to cover tax obligations related to the vesting of restricted stock units. The insider transactions include both sales and acquisitions. On February 20, 2026, Khan acquired 45,000 shares of Caribou Biosciences stock with a value of $0, and also acquired options to purchase 202,500 shares of common stock at an exercise price of $1.80. These options are set to vest monthly, with full vesting scheduled by February 20, 2030. Following these transactions, Khan directly owns 104,998 shares of the company's stock, demonstrating a continued significant stake in the biotechnology firm. The insider activity comes amid strong performance for Caribou Biosciences' stock, which has surged 32% over the past week and 73% over the past year. According to InvestingPro analysis, the stock currently trades below its Fair Value, suggesting potential upside for investors. The company's financial health scores as 'FAIR' overall, with deeper insights available through InvestingPro's comprehensive research reports covering CRBU and over 1,400 US equities. Recent analyst coverage has also provided positive momentum for the company. Clear Street initiated coverage on Caribou Biosciences with a Buy rating and set a price target of $13.00. The firm expressed optimism about the company's development of off-the-shelf allogeneic CAR-T cell therapies, which are anticipated to compete commercially in the market. This analyst endorsement highlights confidence in Caribou Biosciences' strategic direction and potential market impact, likely influencing investor sentiment and providing insights into the company's growth potential in the competitive biotechnology sector.
🏷️ Themes
Insider Trading, Biotechnology, Stock Market Performance, Therapeutics Development
📚 Related People & Topics
Insider trading
Trading using nonpublic information
# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...
Rachel Haurwitz
American biochemist (born 1985)
Rachel Elizabeth Haurwitz (born May 20, 1985) is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
Entity Intersection Graph
Connections for Insider trading:
🌐
SEC filing
5 shared
👤
New York Stock Exchange
4 shared
🌐
ZWS
2 shared
👤
Rachel Haurwitz
2 shared
🌐
Biopharmaceutical
2 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) Khan, Caribou Biosciences CBO, sells $13598 in stock By Investing.com Insider Trading Published 02/24/2026, 08:58 PM Khan, Caribou Biosciences CBO, sells $13598 in stock 0 CRBU 11.46% Ruhi Ahmad Khan, Chief Business Officer of Caribou Biosciences NASDAQ:CRBU , sold 6,938 shares of common stock on February 24, 2026, at a price of $1.96, for a total value of $13598. According to a Form 4 filing with the Securities and Exchange Commission, the transaction was to cover tax obligations related to the vesting of restricted stock units. On February 20, 2026, Khan also acquired 45,000 shares of Caribou Biosciences stock with a value of $0. Furthermore, Khan acquired options to purchase 202,500 shares of common stock at an exercise price of $1.80. These options vest monthly, with full vesting by February 20, 2030. Following these transactions, Khan directly owns 104,998 shares of Caribou Biosciences.The insider activity comes as CRBU stock has surged 32% over the past week, contributing to a remarkable 73% gain over the past year. According to InvestingPro analysis, the stock currently trades below its Fair Value, suggesting potential upside. The platform’s comprehensive Pro Research Report—available for CRBU and 1,400+ US equities—provides deeper insights into the company’s financial health, which scores as "FAIR" overall. In other recent news, Clear Street initiated coverage on Caribou Biosciences with a Buy rating and set a price target of $13.00. The firm expressed optimism about Caribou Biosciences’ development of off-the-shelf allogeneic CAR-T cell therapies. These therapies are anticipated by Clear Street to comp...
Read full article at source